
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Chicago-A higher age at baseline predicted increased rate of progressionin all three treatment arms of the Medical Therapy of Prostate Symptoms(MTOPS) trial, according to a secondary analysis of data presented at theAUA meeting yesterday.





